Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

A new ultra-high-throughput sequencing platform boosts output, speeds turnaround, and improves genome coverage. It reduces costs, broadens clinical applications, and accelerates large-scale genomics ...

CEO Dr Ilian Iliev and Steve Cook, CEO of EMVC portfolio company DName-iT, talked with Proactive's Stephen Gunnion about ...

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...